Get started
Author

Dominic Pilon

Observed names: D Pilon, D. Pilon, Pilon, Dominic
ORCID: 0000-0003-2380-1495
Observed ORCID: 0000-0003-2380-1495
OpenAlex ID: A5111170813
Real-World Comparative Effectiveness And Safety Of Rivaroxaban And Warfarin In Nonvalvular Atrial Fibrillation Patients
2014 · F. Laliberté, M. Cloutier, et al. · Value in Health · 48
PDF
Comparative analysis of persistence and remission with guselkumab versus secukinumab and ixekizumab in the United States
2024 · Maryia Zhdanava, Timothy Fitzgerald, et al. · Journal of Dermatological Treatment · 11
Comparison of Real-World On-Label Treatment Persistence in Patients with Psoriatic Arthritis Receiving Guselkumab Versus Subcutaneous Tumor Necrosis Factor Inhibitors
2024 · Jessica A. Walsh, Iris Lin, et al. · Drugs - Real World Outcomes · 7
Real-World Maintenance Phase Persistence on Ustekinumab and Adalimumab in Ulcerative Colitis
2024 · Maryia Zhdanava, Sumesh Kachroo, et al. · Patient Preference and Adherence · 4
PDF
Prospective patient preference study for Bruton tyrosine kinase inhibitor (BTKi) treatment attributes and factors affecting patient shared decision-making in chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL) in the United States (US)
2026 · Sikander Ailawadhi, Swetha Challagulla, et al. · Expert Review of Hematology · 3
PDF
Economic and clinical burden of major depressive disorder with insomnia symptoms in commercially and Medicaid-insured adults in the United States: A retrospective matched cohort study
2024 · Hrishikesh Kale, Maryia Zhdanava, et al. · Journal of Affective Disorders · 3
Homologous Recombination Repair Testing Patterns and Outcomes in mCRPC by Alteration Status and Race
2024 · Mehmet Bilen, Ibrahim Khilfeh, et al. · ClinicoEconomics and Outcomes Research · 3
Patient medication preferences in follicular lymphoma in the United States: a discrete choice experiment
2026 · Sameh Gaballa, Mei Xue, et al. · Postgraduate Medicine · 2
PDF
Real-World Comparison of Overall Survival Among Patients With and Without Inherited Retinal Diseases
2026 · Byron L. Lam, Carlos E. Mendoza-Santiesteban, et al. · Vision · 1
PDF
Real-world comparison of prostate-specific antigen (PSA) response in metastatic castration-sensitive prostate cancer (mCSPC) patients treated with apalutamide (APA) without docetaxel vs darolutamide (DARO) without docetaxel.
2026 · Mehmet Asim Bilen, Gordon Andrew Brown, et al. · Journal of Clinical Oncology · 1
PDF
Prescriber- and Patient-Level Characteristics Associated with Patient Adherence to Any Antipsychotics Among Patients with Schizophrenia in the United States
2026 · Arthur Voegel, Ronaldo Naranjo, et al. · Patient Preference and Adherence · 1
PDF
Homologous Recombination Repair Mutations, Next-generation Sequencing Testing, and Treatment Progression by Race Among Patients With Metastatic Castration-sensitive Prostate Cancer
2026 · Mehmet A. Bilen, Neal Shore, et al. · Urology · 1
Comparison of deep prostate-specific antigen response in Black patients with metastatic castration-sensitive prostate cancer initiated on apalutamide or enzalutamide
2026 · Benjamin H Lowentritt, Sabree Burbage, et al. · Journal of Comparative Effectiveness Research · 1
Comparison of Prostate-Specific Antigen Response in Black Patients with Metastatic Castration-Sensitive Prostate Cancer Initiated on Apalutamide vs Abiraterone Acetate
2025 · Gordon Brown, Sabree Burbage, et al. · Journal of health economics and outcomes research · 1
On-Label Treatment Persistence Through 24 Months Among Patients with Active Psoriatic Arthritis Initiating Guselkumab or Subcutaneous Tumor Necrosis Factor Inhibitors
2025 · Philip J. Mease, Jessica A. Walsh, et al. · Rheumatology and Therapy · 1
PDF
Mental Health-Related Disability Days and Costs Among Patients with Treatment-Resistant Depression Initiated on Esketamine Nasal Spray and Conventional Therapies in the USA
2025 · Manish K. Jha, Maryia Zhdanava, et al. · Drugs - Real World Outcomes · 1
PDF
Prospective Patient Preference Study for Bruton Tyrosine Kinase Inhibitor (BTKi) Treatment Attributes and Factors Affecting Patient Shared Decision-Making in Chronic Lymphocytic Leukemia (CLL) and Small Lymphocytic Lymphoma (SLL) in the United States (USA)
2024 · Sikander Ailawadhi, Swetha Challagulla, et al. · Blood · 1
PDF
Familial Adenomatous Polyposis
2018 · D Pilon, H Haddad · Elsevier eBooks · 1
Prospective patient preference study for chronic lymphocytic leukemia (CLL) treatment attributes impacting patient shared decision-making
2026 · Sikander Ailawadhi, Swetha Challagulla, et al. · Expert Review of Anticancer Therapy
PDF
Real-world clinical outcomes among patients with localized prostate cancer (LPC) undergoing radical prostatectomy (RP).
2026 · Neal D. Shore, Benjamin H. Lowentritt, et al. · Journal of Clinical Oncology
On-label persistence in psoriasis after switching to guselkumab, tumor necrosis factor inhibitors, interleukin-17 inhibitors, or apremilast from other advanced therapies
2026 · Maryia Zhdanava, Timothy Fitzgerald, et al. · Journal of Dermatological Treatment
PDF
On-label persistence in psoriasis after switching to guselkumab, tumor necrosis factor inhibitors, interleukin-17 inhibitors, or apremilast from other advanced therapies
2026 · Zhdanava, Maryia, Fitzgerald, Timothy, et al. · Figshare
Real-World Comparison of On-Label Treatment Persistence Through 24 Months Between Patients with Psoriatic Arthritis Initiating Guselkumab or Subcutaneous Interleukin-17A Inhibitors
2025 · Philip J. Mease, Jessica A. Walsh, et al. · Advances in Therapy
PDF
Time burden of treatment with parenteral hypomethylating agents in combination with venetoclax among patients with newly diagnosed Acute Myeloid Leukemia
2025 · Amer Zeidan, Ruizhi Zhao, et al. · Blood
PDF
Evaluating patient preferences for chronic lymphocytic leukemia (CLL) in Korea: A discrete choice experiment
2025 · Byung Woo Yoon, Suhyeon Lee, et al. · Blood
Works count: 34
Citation count: 91
H-index: 4
I10-index: 2
Year
Topic
Type